NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis → The #1 Biotech Stock to Have on Your Radar in 2024… (From Huge Alerts) (Ad) Free KTTA Stock Alerts $7.03 -0.21 (-2.90%) (As of 01:16 PM ET) Add Compare Share Share Today's Range$6.90▼$7.0350-Day Range$6.70▼$8.7552-Week Range$5.25▼$17.40Volume1,364 shsAverage Volume9,288 shsMarket Capitalization$7.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Pasithea Therapeutics alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Pasithea Therapeutics Stock (NASDAQ:KTTA)Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More KTTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTTA Stock News HeadlinesApril 29, 2024 | globenewswire.comPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | globenewswire.comPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersApril 29, 2024 | Huge Alerts (Ad)The #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!April 19, 2024 | americanbankingnews.comPasithea Therapeutics (NASDAQ:KTTA) Shares Down 0.4% February 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004January 8, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJanuary 2, 2024 | msn.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | markets.businessinsider.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceApril 29, 2024 | Huge Alerts (Ad)The #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!January 2, 2024 | seekingalpha.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyJanuary 2, 2024 | finance.yahoo.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 1, 2024 | benzinga.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesDecember 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 19, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 13, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?December 11, 2023 | msn.comNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's WhyDecember 11, 2023 | markets.businessinsider.comPasithea Announces Positive In Vivo Preclinical Data For PAS-004December 11, 2023 | msn.comPasithea stock soars as high as 190% on preclinical dataDecember 11, 2023 | investorplace.comWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?December 11, 2023 | finance.yahoo.comPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | msn.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004November 29, 2023 | markets.businessinsider.comPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical DevelopmentNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNovember 9, 2023 | finance.yahoo.comPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSSeptember 14, 2023 | finance.yahoo.comPasithea Therapeutics Corp. Announces Final Results of Tender OfferSeptember 7, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceSee More Headlines Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Next Earnings (Estimated)6/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.04% Return on Assets-45.29% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$20,000.00 Price / Sales376.48 Cash FlowN/A Price / Cash FlowN/A Book Value$22.46 per share Price / Book0.32Miscellaneous Outstanding Shares1,040,000Free Float895,000Market Cap$7.53 million OptionableNot Optionable Beta0.88 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Co-Founder, MD & Executive Chairman Comp: $250kDr. Tiago Reis Marques M.D. (Age 46)Ph.D., CEO & Director Comp: $480kMr. Daniel H. Schneiderman (Age 46)Chief Financial Officer Comp: $345.94kDr. Graeme Currie Ph.D. (Age 57)Chief Development Officer Comp: $346.62kDr. Yassine Bendiabdallah Ph.D. (Age 40)COO & Head of UK Clinics Key CompetitorsChemomab TherapeuticsNASDAQ:CMMBKinetaNASDAQ:KABionomicsNASDAQ:BNOXGraybug VisionNASDAQ:GRAYeFFECTOR TherapeuticsNASDAQ:EFTRView All CompetitorsInsidersLawrence SteinmanBought 1,500 shares on 6/2/2023Total: $12,900.00 ($8.60/share)View All Insider Transactions KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed in 2024? Pasithea Therapeutics' stock was trading at $7.40 on January 1st, 2024. Since then, KTTA shares have decreased by 2.2% and is now trading at $7.24. View the best growth stocks for 2024 here. When is Pasithea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our KTTA earnings forecast. When did Pasithea Therapeutics' stock split? Pasithea Therapeutics shares reverse split before market open on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KTTA) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
